Complement C3a Mouse anti-Human, Clone: 2991, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA140157
MA1-40157 detects C3a/C3a des-Arg from human samples. MA1-40157 has been successfully used in Western blot and ELISA applications. Positive control: Activated human serum or purified human C3a desArg protein; Negative control: For Western blot, any irrelevant protein can be used.The third component of the complement system, C3, is central to the classical, alternative and lectin pathways of complement activation. The synthesis of C3 is tissue-specific and is regulated in response to a variety of stimulatory agents. During complement activation, C3 is proteolytically cleaved resulting in release of the anaphylatoxic peptide C3a (74 amino acids, 10kDa). C3a is short-lived and in serum cleaved rapidly into the more stable C3a-desArg. C3a exerts its function through a specific receptor (C3aR), which belongs to the G-protein coupled receptor family. Expression of C3aR has been reported in many cell types including myeloid and non-myeloid cells, and its expression on haematopoietic stem/progenitor cells has been shown to promote the trafficking/homing of these cells to the BM. C3a is a mediator of local inflammatory processes. It induces smooth muscle contraction, increases vascular permeability, and causes histamine release from mast cells and basophilic leukocytes. C3a is involved in inflammatory reactions seen in gram-negative bacterial sepsis, trauma, ischemic heart disease, postdialysis syndrome and a variety of autoimmune diseases. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections.
|PBS with 0.1% BSA and 0.02% sodium azide|
|AI255234, ASP, Plp|
|ELISA, Western Blot|
|Human C3a des-Arg|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok